EURIPRED is a collaborative programme with the goal to coordinate and integrate international resources into a single specialised infrastructure to support European research on HIV, TB, Malaria and Hepatitis B/ C virus. This will be achieved by creating networks partnerships between European scientists and international research teams (including biobanks) from disease endemic countries, and strong collaborations between industry and public sector research. This integrated approach will strengthen international cooperation, increase research capacity in EU and developing countries and significantly contribute to the European Research Area (ERA). EURIPRED consortium is co-funded with € 8.5 million by the European Commission. EURIPRED offers free access to shared clinical material and reference reagents, and training opportunities. Other scientific activities include standardisation and harmonisation of commonly used immunological assays for assessing the potency of vaccine candidates. The project has successfully passed the mid-term review assessment by the European Commission and is approved to continue activities until October 2017.
Visit our website for more information and free access of services and reagents on EURIPRED